In the last trading session, 4.02 million shares of the Allogene Therapeutics Inc (NASDAQ:ALLO) were traded, and its beta was 1.02. Most recently the company’s share price was $1.80, and it changed around -$0.15 or -7.69% from the last close, which brings the market valuation of the company to $377.41M. ALLO currently trades at a discount to its 52-week high of $5.78, offering almost -221.11% off that amount. The share price’s 52-week low was $1.32, which indicates that the current value has risen by an impressive 26.67% since then.
Allogene Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.56. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 5 recommended ALLO as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Allogene Therapeutics Inc is expected to report earnings per share of -0.32 for the current quarter.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Instantly ALLO has showed a red trend with a performance of -7.69% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.1450 on recent trading dayincreased the stock’s daily price by 16.08%. The company’s shares are currently down -15.49% year-to-date, but still down -15.89% over the last five days. On the other hand, Allogene Therapeutics Inc (NASDAQ:ALLO) is -6.25% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $33.5, which translates to bulls needing to increase their stock price by 94.63% from its current value. Analyst projections state that ALLO is forecast to be at a low of $7 and a high of $55.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
The year-over-year growth rate is expected to be -68.42%, down from the previous year.
Consensus estimates provided by 16 financial analysts predict the company will bring in an average of 10.5k in revenue for the current quarter. 12 analysts expect Allogene Therapeutics Inc to make 4.17k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 21k and 22k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -50.00%. Forecasts for the next quarter put sales growth at -81.05%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 22.18%. Allogene Therapeutics Inc earnings are expected to increase by 36.25% in 2025, but the outlook is positive 11.41% per year for the next five years.
ALLO Dividends
Allogene Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
TPG GP A, LLC, with 9.8493% or 18.72 million shares worth $43.61 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Smallcap World Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 6.9 shares worth $12.41 million, making up 3.29% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 4.34 shares worth around $7.81 million, which represents about 2.07% of the total shares outstanding.
